H eart failure (HF) is estimated to affect ≈2% of the worldwide population, with an incidence approaching 10 per 1000 persons per year. These numbers are expected to increase with population growth projections, especially of the elderly. 1 Half of patients have preserved (HFpEF) or mildly reduced (mid-range: HFmrEF) ejection fraction (EF). Overall prognosis is as poor as in reduced EF (HFrEF), 2 whereas HFpEF patients show higher hospitalization rates and die more often of noncardiovascular causes.
NT-proBNP Changes in HFpEF and HFmrEF
NT-proBNP is also being used for eligibility in trials enrolling HFpEF and HFmrEF patients, both to ensure the presence of HF and to enrich the population for HF-related outcomes. However, there are currently no feasible surrogate end points for early-phase HFmrEF and HFpEF trials. Although it would be intuitive, it is unknown whether changes in NT-proBNP correlate with outcomes and, thus, whether changes in NT-proBNP is a potential surrogate end point for phase II HFmrEF and HFpEF trials.
Therefore, the aim of the present study was to investigate whether changes in NT-proBNP levels are associated with the risk of death and HF hospitalization in a large cohort of unselected patients with HFmrEF and HFpEF.
Methods

Study Protocol and Setting
The Swedish Heart Failure Registry (SwedeHF; www.SwedeHF.se) has been previously described. 11 ; a HF diagnosis was verified in between 86% and 91% of cases. 12 Statistics Sweden (www.scb.se) maintains socioeconomic data on all Swedish citizens and provides additional baseline data. All Swedish citizens have unique personal identification numbers that enable linking of disease-specific health registries and governmental health and statistical registries.
Establishment of the HF registry and this analysis with linking of the above registries were approved by a multisite ethics committee. Individual patient consent was not required, but patients were informed of entry into national registries and allowed to opt out.
The Registry includes patients without any limitation regarding EF. EF is categorized as <30%, 30% to 39%, 40% to 49%, and ≥50%.
In the current study, outpatients with EF ≥40% with at least 2 consecutive NT-proBNP levels assessment were selected. EF 40% to 49% is not considered normal or preserved, but there is currently no evidence-based therapy in this group, and future trials should address this mid-EF range and strictly preserved EF (EF ≥50%). Nevertheless, we performed separate analyses in HFmrEF (EF 40% to 49%) and HFpEF (EF ≥50%) groups. When a patient reported more than one NT-proBNP measurement at the follow-up, the value considered was the one obtained at the closest visit to 6 months of follow-up from the first registration. Because shorter term follow-up is most relevant for phase II trials, we also performed a subgroup analysis in patients with the second NT-proBNP value at ≤6 months. The index date was defined as the outpatient clinic visit for HF, occurring between 2000 and December 30, 2012, at which the second NT-proBNP measurement was performed. The outcomes HF hospitalization and all-cause mortality were defined as between the index date and end of followup, December 31, 2012, for which an HF diagnosis was required as the primary diagnosis for hospitalization. A composite outcome of HF hospitalization and mortality was also considered.
Statistical Analysis
Change in NT-proBNP levels was expressed as the percent variation between the 2 peptide measurements (%ΔNT-proBNP=[final NTproBNP−baseline NT-proBNP]/baseline NT-proBNP*100).
Baseline Characteristics
Baseline characteristics at the time of the first NT-proBNP measurement of patients, who subsequently showed an increase versus those who reported a reduction in NT-proBNP levels, were compared by t test or χ 2 test to test continuous and categorical variables, respectively. Missing baseline characteristics were reported as percent missing in the baseline characteristics (Table 1 ) and managed by multiple imputation (n=10) in multivariable models.
Association Between Changes in NT-proBNP and Outcomes
We modeled changes in NT-proBNP as a quantitative predictor of event rates either assuming a linear or curvilinear dose-response relationship. In particular, we used restricted cubic splines to flexibly model potential nonlinearity.
The relationship between changes in NT-proBNP and outcomes was also assessed using NT-proBNP changes as a dichotomous variable (increase versus decrease in NT-proBNP levels, as categorized in Table 1 ). For the 2 groups (increase versus decrease in NT-proBNP) and for each of the outcome, the raw number of events was reported. To estimate the size of the association between NT-proBNP decreases (versus increases) on end points, proportional hazard ratios (HR) with 95% confidence intervals (CI) were calculated with Kaplan-Meier analyses and then adjusted with Cox proportional hazard models.
We also performed Cox regressions with NT-proBNP categories obtained by dividing the cohort of patients into 4 groups based on the median values of NT-proBNP levels at the baseline and at the follow-up visit: low levels at the baseline and low at the follow-up evaluation (stable low levels of NT-proBNP), low at the baseline and high at the follow-up evaluation (increase in NT-proBNP levels), high at the baseline and low at the follow-up evaluation (decrease in NT-proBNP levels), and high at the baseline and high at the followup evaluation (stable high levels of NT-proBNP; reference group).
All the Cox regression models reported in the current analyses were adjusted for the variables that correlated with at least one outcome at the univariate analysis with a P value ≤0.05.
Associations Between Baseline Variables and Subsequent Decease in NT-proBNP
Multivariable logistic regression, using decreases in NT-proBNP as dependent variable and all the variables correlating with decreases in NTproBNP at the univariate analysis as covariates, with a P value ≤0.05, was run to detect the predictors of decrease in NT-proBNP levels.
Results
Patients
Between May 11, 2000, and December 30, 2012, 55 821 registrations were recorded from 34 188 unique patients. Of these, 650 were outpatients with HFmrEF (40% to 49%; n=380) or HFpEF (left ventricular EF ≥50%; n=270) and reported at least 2 outpatient NT-proBNP measurements.
Baseline Characteristics
Baseline characteristics are reported in Table 1 . In Table I in the Data Supplement, the cohort of HFpEF/HFmrEF outpatients with 2 NT-proBNP measurements considered in the current study has been compared with the overall HFpEF/HFmrEF outpatient cohort of the SwedeHF for baseline characteristics. Mean age was 73±12 years, 40% were women, the median Figure I in the Data Supplement), and the median follow-up was 1.65 years (interquartile range 0.70-2.82 years). Patients who showed a decrease compared with those who reported an increase in NTproBNP levels had a shorter duration of HF, higher levels of baseline NT-proBNP, more history of myocardial infarction, and less atrial fibrillation. Additionally, trends toward younger age and more frequent specialist care were observed in patients who had decrease in NT-proBNP. HFmrEF versus HFpEF was more common in those with a decrease in NT-proBNP (62% versus 38%) than in those with an increase (54% versus 46%).
Changes in NT-proBNP and Outcomes
We found strong evidence of nonlinearity (P<0.001) between NT-proBNP changes and event rates ( Figure 1 ). The rate of change in risk of clinical outcomes depended on the actual values of change in NT-proBNP. A strong inverse association for those with a decrease in NT-proBNP and positive association for those with an increase NT-proBNP were reported (Table 2; Figure 1 ). Of 650 patients (1052.23 patient-years), 361 (55%; 653.41 patient-years) showed a decrease in NT-proBNP levels versus 289 (45%; 398.82 patient-years) who reported an increase (Figure 2 ).
Fifty-seven deaths (16%; 87 per 1000 patient-years) occurred in patients who showed a decrease in NT-proBNP levels versus 78 (27%; 196 per 1000 patient-years) in those who reported an increase (Figure 3 ). After adjustments, the HR for all-cause death was 0.53 (95% CI, 0.36-0.77) for patients reporting a decrease versus those showing an increase in NT-proBNP (Table 3) . Sixty-one HF hospitalizations (17%; 93 per 1000 patient-years) were reported in patients who decreased NT-proBNP levels versus 86 (30%; 216 per 1000 patient-years) in those who showed an increase in peptides levels ( Figure 3 ). After adjustment, the HR for HF hospitalization was 0.41 (95% CI, 0.29-0.60) for patients reporting a decrease versus those showing an increase in NT-proBNP levels at the follow-up (Table 3 ). The composite outcome occurred in 96 patients (27%; 147 per 1000 patient-years) reporting a decrease in NT-proBNP levels versus 125 (43%; 313 per 1000 patient-years) of those showing an increase in peptides levels ( Figure 3 ). After adjustments, the HR for the composite outcome was 0.46 (95% CI, 0.34-0.62) for patients who showed a decreased NT-proBNP levels versus those who reported an increase in peptides levels at the follow-up (Table 3) .
When the analysis was limited to those patients with time between NT-proBNP evaluations ≤ 6 months (n=269), the HR was 0.43 (95% CI, 0.23-0.81) for all-cause death, 0.64 (95% CI, 0.37-1.10) for HF hospitalization, and 0.62 (95% CI, 0.39-0.99) for the composite outcome. EF indicates ejection fraction; HF, heart failure; IQR, interquartile range; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and NYHA, New York Heart Association.
EF Subgroups
*Variables significantly associated with the risk of overall mortality or of HF hospitalization or of the composite outcome and were included in the Cox regression model together with percent changes in NT-proBNP levels.
†Creatinine clearance was calculated by Cockcroft-Gault formula. Table 3) .
Combinations of NT-proBNP at First and Second Occasions
Importantly, when taking both NT-proBNP values into account, patients reporting a decrease of NT-proBNP had an improved prognosis as compared with those with stable high peptide levels. Additionally, no difference in risk of all the outcomes was reported between patients reporting a reduction of NTproBNP and those with stable low levels of peptides, and between patients showing an increase in NT-proBNP and those with stable high levels of peptides (Table II and 
Predictors of NT-proBNP Decrease
Of all the variables tested, the decrease of NT-proBNP levels was independently predicted by shorter HF duration (odds ratio 
Discussion
In HFmrEF and HFpEF patients enrolled in the SwedeHF, a large prospective registry of unselected patients with HF, larger reductions of NT-proBNP over a median of 7 months were associated with lower mortality and HF hospitalization rates. In particular, a reduction versus an increase in NT-proBNP levels was associated with a reduced risk of all-cause death by 47%, of HF hospitalization by 59% and of their composite by 54%. This observation was consistent in both patients with HFpEF (EF Figure 1 . Association between continuous percent changes in N-terminal pro-B-type natriuretic peptide (NT-proBNP) from baseline to follow-up evaluation and risk of all-cause death, heart failure (HF) hospitalization, and composite outcome. Data were fitted with a restricted cubic splines Cox regression models. Data were fitted with restricted cubic splines Cox regression models. CI indicates confidence interval; HF, heart failure; HR, hazard ratio; and NTproBNP, N-terminal pro-B-type natriuretic peptide. ≥50%) and in those with HFmrEF (EF 40%-49%). Furthermore, the importance of achieving a reduction of NT-proBNP over time was illustrated by those with high values at time 1 and low values at time 2, who had an improved prognosis as compared with patients with stable high NT-proBNP levels.
Need for Surrogate End Points
Currently, no specific treatment for HFmrEF and HFpEF has been established, and the management is limited to symptomatic relief with diuretics and treatment of comorbidities because ACE-Is, 13 ARBs, 14, 15 digoxin, 16 β-blockers, 17 and mineralocorticoid receptor antagonists 18 have not convincingly been demonstrated to improve outcomes in phase III clinical trials. The lack of benefit of these drugs could be explained by heterogeneous phenotypes of HFpEF and HFmrEF and by the absence of phase II data, leading to difficulty defining eligibility criteria and end points. Thus, improved early-phase HFpEF and HFmrEF trial design for potential existing and novel interventions may improve the likelihood of successful phase III trials and would be facilitated by feasible and meaningful surrogate end points. Diastolic dysfunction, increased left ventricular mass and mass/volume ratio, left atrial size, diastolic wall stress, exercise capacity, peakVO 2 , and natriuretic peptide levels evaluation have been considered as potential structural and functional targets and surrogate end points in phase II trials in HFpEF/HFmrEF because these have been demonstrated to independently predict outcomes. 4 To our knowledge only, reductions in left atrial volume have been demonstrated to translate into improved morbidity or mortality, as suggested by a post hoc analysis from TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist). 19 However, this was the case in both the spironolactone and placebo groups. Furthermore, in the Americas subgroup, where spironolactone was purportedly effective, 20 it did not reduce left atrial volume. 19 Therefore, although reductions in NT-proBNP in our study and left atrial volume in TOPCAT were associated with improved outcomes, this is not the same as a treatment effect and does not adequately support such changes being used as surrogate trial end points. Conversely, phase II studies assessing the efficacy and safety of long-term mineralocorticoid receptor antagonist use in HFpEF demonstrated improved left ventricular Figure 2 . Baseline, final, and %ΔN-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in patients reporting a decrease or an increase in NT-proBNP levels. Figure 3 . Kaplan-Meier curves fitted for all-cause death, heart failure (HF) hospitalization, and the composite outcome using decreases vs increases in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels.. diastolic function, 21, 22 but the following phase III trial, TOPCAT, showed no effect in the overall trial on the primary outcome (composite of death from cardiovascular causes, aborted cardiac arrest, or HF hospitalization), 18 although this analysis may have been confounded by regional differences in patients and treatment effect. 20 It is, therefore, no surprise that other interventional phase II trials showing beneficial effects on some of these putative surrogate end points have not been followed by positive phase III trials. [13] [14] [15] 18, 21 Thus, there is still an urgent need to develop new valid surrogate end points for well-designed phase II HFpEF and HFmrEF trials.
Single Measurements of NT-proBNP
Several studies assessed the prognostic value of plasma concentrations of BNP and NT-proBNP in patients with HFpEF and HFmrEF. [23] [24] [25] In I-PRESERVE (Irbesartan in Heart Failure with Preserved Ejection Fraction Study), baseline NT-proBNP >339 pg/mL was independently associated with increased rates of all-cause mortality, of the composite of all-cause mortality and cardiovascular hospitalization, and of the composite of death for HF and sudden death and HF hospitalization. 23 Similarly, in PEP-CHF (Perindopril in Elderly People with Chronic Heart Failure), a progressive increase in morbidity and mortality was observed with increasing quartiles of NT-proBNP, and in CHARM-Preserved (Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity), NT-proBNP >600 pg/mL was the sole predictor of the primary outcome, the composite of cardiovascular mortality, HF hospitalization, myocardial infarction, or stroke. 24, 25 Certainly, we confirmed that lower NT-proBNP is favorable, with dramatically better prognosis with NT-proBNP below median at the follow-up visit. However, patients going from high to low versus from low to low, as well as patients going from low to high versus from high to high, had similar outcomes, that is, the baseline NT-proBNP was irrelevant, as long as the follow-up value was low (below median). This suggests that individual patient characteristics regarding natural history and interventions that favorably affect subsequent NT-proBNP values are more important than where the patient starts out, also lending support to the use of changes in NT-proBNP as surrogate marker in phase II HFpEF/HFmrEF trials.
Changes in NT-proBNP
Although the impact of single evaluations of NT-proBNP on prognosis in patients with EF ≥40 has been well studied, the role of changes in NT-proBNP levels over time has been studied only in HFrEF 26 and in one single previous report in patients with HFpEF or HFmrEF. 27 The latter was a post hoc analysis of I-PRESERVE, enrolling 2612 patients with EF ≥45%, where a decrease and increase in NT-proBNP levels <1000 pg/mL from baseline to 6-month follow-up was associated with a 27% reduction and 2-fold increase in rates of cardiovascular death or HF hospitalization, respectively, whereas beyond a 1000 pg/mL rise or fall, there was only little change in risk. 27 However, these findings coming from a randomized clinical trial, which by their nature are highly selective and while internally valid, may not be representative of the heterogeneity, comorbidity, and resulting competing events of HF patients in the community and thus have limited external validity and generalizability. 
Predictors of Reduction in NT-proBNP
In our cohort of 650 unselected patients with HFpEF or HFmrEF, 45% of the subjects showed a decrease in NT-proBNP levels versus 55% who reported an increase in peptides levels. CI indicates confidence interval; EF, ejection fraction; HF, heart failure; HFmrEF, heart failure with midrange ejection fraction; HFpEF, heart failure with preserved ejection fraction; HR, hazard ratio; and NT-proBNP, N-terminal pro-B-type natriuretic peptide.
A decrease in NT-proBNP was predicted by several baseline characteristics. Use of ACE-Is and ARBs has not been shown to improve outcomes in randomized trials, 14, 15 but large observational studies, including one from SwedeHF, suggest that they may be associated with improved outcomes. 9 In the present study, the use of ACE-Is or ARBs was also independently associated with reductions in NT-proBNP, suggesting but not proving, that if an intervention reduces NT-proBNP, it also improves outcomes, a fundamental characteristic of an appropriate surrogate end point. We also observed that sinus rhythm but not atrial fibrillation was related to a decrease of NT-proBNP. Because atrial fibrillation is associated with enlarged left atrial volume and more elevated levels of NT-proBNP, 31 it is conceivable that a decrease of natriuretic peptide levels is more difficult to achieve in patients with HFpEF/HFmrEF and concomitant atrial fibrillation.
Study Limitations
Our observational study is subject to selection bias and confounding. Additionally, in this real-world setting, there was some missing data, which was handled by multiple imputation. SwedeHF, together with population-wide registries, provided a large amount of baseline variables known to influence outcomes that were adjusted for in multivariable analyses. However, we cannot exclude that the adjustments at the multivariable analysis were not sufficient to rule out the effects of potential confounders on our analysis. In our analysis, we considered cause-specific hospitalization but not cause-specific death, and this is another limitation.
Our data are not from a trial, and the reductions in NT-proBNP reflect real-life standard of care rather than any specific intervention. Therefore, we cannot show that a reduction in NT-proBNP that might occur in a trial also would translate into improved outcomes. We also acknowledge that, given the >55 821 registrations and >34 188 unique patients, the sample size of 650 is small. NT-proBNP was not widely available and used in the early 2000s. Furthermore, NT-proBNP is indicated in Sweden for diagnosis of and prognosis in HF but currently not for serial follow-up or guiding therapy. Therefore, longer surviving patients may have had longer time to get a repeat measurement (survival bias), but on the contrary, deteriorating patients may also have had a greater indication for a repeat measurement (bias by indication). Although we cannot rule out such biases, this should affect survival in opposite directions, and the overall survival at 1 year (14.3%) was similar to other reports from outpatients in HFpEF/HFmrEF from SwedeHF. 9, 31 Additionally, the mentioned limitations did not allow us to perform the analyses calculating the change in peptide levels at different time points (ie, 3, 6, 9, and 12 months).
Finally, patients were included in SwedeHF based on clinician-judged HF. Thus, we cannot rule out that few patients with preserved left ventricular EF may not have HF.
Conclusions
The current study provides evidence of a strong relationship between reduction in NT-proBNP levels and subsequent lower risk of all-cause death, HF hospitalization, and their composite. These findings suggest that changes in NT-proBNP have potential as a surrogate end point for future phase II HFpEF and HFmrEF clinical trials, but studies to verify whether NTproBNP changes predict drug efficacy are still required.
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